xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorLinhares, Alexandre da Costa-
dc.contributor.authorMacias-Parra, Mercedes-
dc.contributor.authorSáez-Llorens, Xavier-
dc.contributor.authorVergara, Rodrigo-
dc.contributor.authorJimenez, Elias-
dc.contributor.authorVelázquez, F. Raul-
dc.contributor.authorCervantes, Yolanda-
dc.contributor.authorAbate, Héctor José-
dc.contributor.authorRivera, Luis-
dc.contributor.authorRuttimann, Ricardo-
dc.contributor.authorRivera-Medina, Doris Maribel-
dc.contributor.authorSalinas, Belén-
dc.contributor.authorOrtega-Barria, Eduardo-
dc.contributor.authorRubio, Pilar-
dc.contributor.authorBreuer, Thomas B-
dc.date.accessioned2018-07-19T13:05:16Z-
dc.date.available2018-07-19T13:05:16Z-
dc.date.issued2012-
dc.identifier.citationLINHARES, Alexandre da Costa et al. Rotavirus gastroenteritis in Latin America: a hospital-based study in children under 3 years of age. Trials in Vaccinology, v. 1, p. 36-41, 2012.pt_BR
dc.identifier.issn1879-4378-
dc.identifier.urihttp://patua.iec.gov.br//handle/iec/3267-
dc.description.abstractRotavirus is the leading cause of severe diarrheal disease and dehydration in infants in both developed and developing countries. Vaccines have recently been developed, but detailed epidemiological information, which is needed for decisions about how and where to introduce vaccination, was lacking for many Latin American countries. The primary objective of this study was to measure the incidence and disease burden of rotavirus in young children presenting to Latin American hospitals with gastroenteritis. In addition it allowed to setting up the methodology to further conduct a large phase III trial with a rotavirus vaccine in the region. This was a prospective, multi-center surveillance study of gastroenteritis in children <3 years old presenting to hospitals in 11 Latin American countries. Questionnaires and stool samples were collected from 6521 of 8031 enrolled cases (73% inpatients). Among these, 3122 (49%) were rotavirus positive. Of the rotavirus-positive cases, 12% were <6 months, 48% <1 year and 87% <2 years old; 23% received antibiotics before diagnosis. Median hospital stay was 2 days, 78% received intravenous rehydration. Overall strain distribution was G1 (59%), G2 (1%), G3 (12%), G4 (20%), G9 (6%), G12 (1%), untypable (7%) with large local variations. The direct economic impact on families was considerable: 48% of caregivers lost time from paid work and 69% of families were financially affected by their child's illness. This study confirms the high disease burden of rotavirus gastroenteritis among children in Latin America, which might be reduced by the use of effective vaccines.pt_BR
dc.description.sponsorshipGlaxoSmithKline (GSK) Biologicals was the funding source and was involved in all stages of the study conduct and analysis. GSK Biologicals also funded all costs associated with the development and the publishing of the present manuscript.pt_BR
dc.language.isoenGpt_BR
dc.publisherElsevierpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleRotavirus gastroenteritis in Latin America: a hospital-based study in children under 3 years of agept_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryGastroenteritept_BR
dc.subject.decsPrimaryInfecções por Rotaviruspt_BR
dc.subject.decsPrimaryVacinas contra Rotaviruspt_BR
dc.subject.decsPrimaryDiarreiapt_BR
dc.subject.decsPrimaryRotavíruspt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationInstituto Nacional de Pediatría. México D.F., Mexico.pt_BR
dc.creator.affilliationHospital del Niño. Panama City, Panama.pt_BR
dc.creator.affilliationUniversidad de Valparaíso. Escuela de Medicina. Valparaíso, Chile.pt_BR
dc.creator.affilliationInstituto Costarricense de Investigaciones Clínicas. Urbanización de Los Arboles La Uruca. San José, Costa Rica.pt_BR
dc.creator.affilliationInstituto Mexicano del Seguro Social. CMN-SXX. Pediatrics Hospital. Medical Research Unit on Infectious Diseases. Mexico City, Mexico.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals México. México D.F., México.pt_BR
dc.creator.affilliationHospital Dr. Humberto Notti. Villa Nueva de Guaymallén, Mendoza, Argentina.pt_BR
dc.creator.affilliationHospital Maternidad Nuestra Sra de la Altagracia. Santo Domingo, D.N., Dominican Republic.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals Argentina. Victoria, Buenos Aires, Argentina.pt_BR
dc.creator.affilliationOrganización para el Desarrollo y la Investigación Salud en Honduras. Colonia Humuya, Sendero Pastizal, Tegucigalpa, Honduras.pt_BR
dc.creator.affilliationCiudad Hospitalaria Dr. Enrique Tejera. Hospital de Niños Dr. Jorge Lizarraga. Carabobo, Valencia, Venezuela.pt_BR
dc.creator.affilliationFundación para el Avance de la Investigación Clínica y Translacional. Consultores Médicos América. Vía España, Carrasquilla, Panama.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals Costa Rica. San Jose, Costa Rica.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals Belgium. Rixensart, Belgium.pt_BR
dc.identifier.doi10.1016/j.trivac.2012.07.002-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple